SCHEMBL2889216

SCHEMBL2889216

NC(=S)c1ccc(OC(=O)Cc2ccccc2Nc2c(Cl)cccc2Cl)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 3/20 0.57
CYP2C9 P11712 2/20 0.57
USP2 O75604 1/20 0.57
LMNA P02545 1/20 0.57
TBXA2R P21731 1/20 0.57
MAPK1 P28482 1/20 0.57
KMT2A Q03164 1/20 0.57
PTGS2 P35354 5/20 0.55
PTGS1 P23219 2/20 0.55
AKR1B10 O60218 1/20 0.55
UGT1A9 O60656 1/20 0.55
TRPA1 O75762 1/20 0.55
ABCB11 O95342 1/20 0.55
MT-CO2 P00403 1/20 0.55
ALB P02768 1/20 0.55
CXCL8 P10145 1/20 0.55
UGT1A6 P19224 1/20 0.55
UGT1A1 P22309 1/20 0.55
CXCR1 P25024 1/20 0.55
ADRA1A P35348 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2881532 0.91 TTR (0.59) TTRCYP2C9USP2LMNATBXA2R
SCHEMBL15267398 0.89 TTR (0.57) TTRCYP2C9USP2LMNATBXA2R
SCHEMBL18613972 0.87 TTR (0.63) TTRCYP2C9USP2LMNATBXA2R
SCHEMBL13299191 0.86 TTR (0.70) TTRCYP2C9USP2LMNATBXA2R
SCHEMBL15542423 0.83 TTR (0.67) TTRCYP2C9USP2LMNATBXA2R
SCHEMBL21401012 0.82 TTR (0.57) TTRCYP2C9USP2LMNATBXA2R
SCHEMBL2885873 0.81 TTR (0.56) TTRCYP2C9USP2LMNATBXA2R
SCHEMBL2880887 0.81 PTGS2 (0.64) TTRCYP2C9USP2LMNATBXA2R
SCHEMBL15591118 0.81 TTR (0.53) TTRCYP2C9USP2LMNATBXA2R
SCHEMBL10801160 0.80 TTR (0.57) TTRCYP2C9USP2LMNATBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022115952-A1 [1-(4-CHLORO-BENZOYL)-5-METHOXY-2-METHYL-1H-INDOL-3-YL]-ACETIC ACID 4-THIOCARBAMOYL-PHENYL ESTER FOR THE TREATMENT OF A VIRAL INFECTION ANTIBE THERAPEUTICS INC. (CA) 2022-06-09 WO disclosed
WO-2022115952-A1 [1-(4-CHLORO-BENZOYL)-5-METHOXY-2-METHYL-1H-INDOL-3-YL]-ACETIC ACID 4-THIOCARBAMOYL-PHENYL ESTER FOR THE TREATMENT OF A VIRAL INFECTION ANTIBE THERAPEUTICS INC. (CA) 2022-06-09 WO disclosed
US-8541398-B2 Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs ANTIBE THERAPEUTICS INC. (CA) 2013-09-24 US disclosed
US-8541398-B2 Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs ANTIBE THERAPEUTICS INC. (CA) 2013-09-24 US disclosed
US-8541398-B2 Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs ANTIBE THERAPEUTICS INC. (CA) 2013-09-24 US disclosed
EP-2057139-B1 HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ANTIBE THERAPEUTICS INC (US) 2013-09-04 EP disclosed
EP-2057139-B1 HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ANTIBE THERAPEUTICS INC (US) 2013-09-04 EP disclosed
US-8314140-B2 4-hydroxythiobenzamide derivatives of drugs ANTIBE THERAPEUTICS INC. (CA) 2012-11-20 US disclosed
US-8314140-B2 4-hydroxythiobenzamide derivatives of drugs ANTIBE THERAPEUTICS INC. (CA) 2012-11-20 US disclosed
US-8314140-B2 4-hydroxythiobenzamide derivatives of drugs ANTIBE THERAPEUTICS INC. (CA) 2012-11-20 US disclosed
US-20090306412-A1 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS ANTIBE THERAPEUTICS INC. (CA) 2009-12-10 US disclosed
EP-2057139-A1 HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS Antibe Therapeutics Inc. (US) 2009-05-13 EP disclosed
EP-2041108-A1 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS Antibe Therapeutics Inc. (US) 2009-04-01 EP disclosed
WO-2008009118-A1 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS ANTIBE THERAPEUTICS INC. (CA) 2008-01-24 WO disclosed
WO-2008009118-A1 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS ANTIBE THERAPEUTICS INC. (CA) 2008-01-24 WO disclosed
WO-2008009127-A1 HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ANTIBE THERAPEUTICS INC. (CA) 2008-01-24 WO disclosed
WO-2008009127-A1 HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ANTIBE THERAPEUTICS INC. (CA) 2008-01-24 WO disclosed
US-20080004245-A1 HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ANTIBE THERAPEUTICS INC. (CA) 2008-01-03 US disclosed
US-20080004245-A1 HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ANTIBE THERAPEUTICS INC. (CA) 2008-01-03 US disclosed
US-20080004245-A1 HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ANTIBE THERAPEUTICS INC. (CA) 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306412-A1 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS HRH4, HRH2, HNMT TTR 3884/4885CYP2C9 160/4885USP2 1771/4885
US-20080004245-A1 HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS PTGS1, HPGDS, PTGES TTR 2885/4885CYP2C9 89/4885USP2 1542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.